3434 A UK national phase I/II clinical trial of a MEK1/2 inhibitor combined with highly active anti-retroviral therapy for HIV-associated Kaposi's sarcoma. (September 2015) - Young, R.; Poyser, C.; Crack, L.; Dockrell, D.; Bowman, C.; Billingham, L.; Bower, M.; Westwell, S.; Leahy, M.; Woll, P.